

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**HARBOUR**  
**BIOMED**  
**和 鉑 醫 藥 控 股 有 限 公 司**  
**HBM Holdings Limited**  
*(incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 02142)**

**POSITIVE PROFIT ALERT**

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review of the Group’s unaudited management accounts for the six months ended 30 June 2025 (the “**Reporting Period**”), the profit for the six months ended 30 June 2025 is expected to be within the range of approximately US\$68 million (equivalent to approximately HK\$532 million) to approximately US\$74 million (equivalent to approximately HK\$579 million). The anticipated increase in profit was mainly attributable to:

- The continued strategic partnerships with global pharmaceutical companies, such as the global strategic collaboration with AstraZeneca PLC (“**AstraZeneca**”);
  - We have received the gross proceeds from the allotment and issue of the subscription shares and partial upfront, milestone and option exercise fees amounting to approximately US\$175 million.
- Newly secured out-licensing and collaboration of innovative products contributed significantly to the revenue for the six months ended 30 June 2025 and such revenue generated from business development activities has transformed into normalized revenue stream of the Company;

As of the date of this announcement, the Company is still in the process of finalizing the interim results of the Group for the six months ended 30 June 2025. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited consolidated management accounts of the Group for the Reporting Period currently available to the Company, and is not based on any figures or information which have been reviewed or confirmed by the audit committee of the Board (the “**Audit Committee**”), or reviewed or audited by the auditors of the Company. The actual results of the Group for the Reporting Period may differ from those disclosed in this announcement. They shall not be taken as a measure or indication of the Group’s current or future operating or financial performance nor shall they be taken as a representation by the Group of the corresponding figures as may be provided in due course in the Company’s interim results announcement for the Reporting Period, which is expected to be published by the end of August 2025 in accordance with the requirements of the Listing Rules. As such, the above figures are provided for Shareholders’ and investors’ reference only. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the Reporting Period.

**Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors are advised to seek professional advice from professional or financial advisers.**

By order of the Board  
**HBM Holdings Limited**  
**Dr. Jingsong Wang**  
*Chairman and Executive Director*

Hong Kong, 28 July 2025

*As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.*